• Tissue factor pathway inhibitor (TFPI) is an antagonist of FXa and the TF-FVIIa complex.
Summary. Background: Tissue factor pathway inhibitor (TFPI) is a protease inhibitor of the tissue factor-activated factor VII complex and activated FX. PF-06741086 is a mAb that targets TFPI to increase clotting activity. Objectives: This study was a randomized, doubleblind, sponsor-open, placebo-controlled, single intravenous or subcutaneous dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086. Patients/Methods: Volunteers who provided written informed consent were assigned to cohorts with escalating dose levels. Safety endpoints included treatment-emergent adverse events (TEAEs), infusion/injection site reactions, vital signs, electrocardiogram, and coagulation and hematology laboratory parameters. Pharmacokinetic (PK) and pharmacodynamic (PD) endpoints included exposures of PF-06741086 in plasma and measures of PF-06741086 pharmacology, respectively. Results: Forty-one male volunteers were recruited overall. Thirty-two were dosed with PF-06741086 from 30 mg subcutaneously to 440 mg intravenously. All doses were safe and well tolerated. TEAEs were mild or moderate in severity, laboratory abnormalities were transient, there were no serious adverse events, there were no infusion/injection site reactions, and no dose escalation stopping criteria were met. Plasma exposures of PF-06741086 increased greater than proportionally with dose under the same dosing route. Coagulation pharmacology was demonstrated via total TFPI, dilute prothrombin time, D-dimer, prothrombin fragment 1 + 2 and thrombin
Introduction
Prophylactic treatment with factor VIII or FIX products has been shown to reduce the frequency of bleeding episodes and give improved orthopedic outcomes in individuals with severe hemophilia A or hemophilia B, respectively. Effective prophylaxis with FVIII or FIX coagulation factor products requires frequent intravenous infusions and is compromised by the production of inhibitors of FVIII or FIX. Augmentation of the extrinsic/initiation pathway is an alternative approach to achieving a procoagulant prophylactic treatment effect that would not be affected by antifactor inhibitors [1] .
The initiation pathway for coagulation is negatively regulated by the serine protease inhibitor tissue factor (TF) pathway inhibitor (TFPI), which is present in the plasma, on the surfaces of endothelial cells, within platelets, and bound to LDLs. There are three forms of TFPI, with the two predominant forms (TFPIa and TFPIb) containing both Kunitz-1 (K1) and Kunitz-2 (K2) inhibitory domains [2] . The K1 domain of TFPI binds to the TF-activated FVII (FVIIa) complex, and the K2 domain binds to the activation site of FX [3] . TFPIa and TFPIb have been shown to cause comparable levels of inhibition of coagulation, indicating that the additional Kunitz-3 domain of TFPIa may have little inhibitory effect [4] . The binding of TF-FVIIa via the K1 domain of TFPI may be dependent on the binding of TFPI to the activation site of FX via its K2 domain [5] . Furthermore, the K2 domain may have a specific function in TFPIa, along with its basic C-terminal region, in its inhibition of the activated FX (FXa)-activated FV complex prothrombinase [6] . Thus, inhibition of the K2 domain of TFPI is an attractive target for pharmacological intervention.
PF-06741086 is a fully human monoclonal immunoglobulin of the G isotype, subclass 1 (IgG 1 ) that targets the K2 domain of TFPI with a binding affinity in the low nanomolar to subnanomolar range (D. D. Pittman, J. Apgar, M. Jin, S. Benard, S. Z. Juo, S. R. Hett, R. Jasuja, S. Rakhe, M. Stahl, J. E. Murphy, in preparation). In vitro thrombin generation assays (TGAs) and dilute prothrombin time (dPT) assays evaluating PF-06741086 added to donor plasma from healthy normal volunteers and patients with hemophilia A, hemophilia B and hemophilia A with inhibitors have all shown the ability of PF-06741086 to increase coagulation activity and promote hemostasis [7] . In addition, the hemostatic efficacy of PF-06741086 was demonstrated in severe injury (tail-transection) models in both hemophilia A and hemophilia B mice [8] . These non-clinical experiments established the pharmacodynamic (PD) rationale for proceeding to clinical studies of PF-06741086.
Study B7841001 (NCT02531815) was a phase 1 single ascending dose study in healthy male volunteers. The primary objective of B7841001 was to evaluate the safety and tolerability of PF-06741086; secondary objectives were to evaluate its pharmacokinetics, pharmacodynamics, and immunogenicity. As the proposed indication for PF-06741086 is the treatment of patients with hemophilia A or B, the single-dose safety profile in a healthy volunteer population was also expected to provide a conservative estimate of safety that might be observed in hemophilic patients following clotting factor replacement therapy.
Materials and methods

Trial design
B7841001 was conducted under a clinical trial application at a single site in Brussels, Belgium (Pfizer Clinical Research Unit Brussels). This study was approved by the comit e d' ethique hospitalo-facultaire Erasme, and was conducted in compliance with the International Conference on Harmonization -Guideline for Good Clinical Practice and the Declaration of Helsinki. All volunteers were required to provide written informed consent prior to any study-related procedures.
Key eligibility criteria for the healthy male volunteers were: age 18-55 years; body mass index (BMI) of 17. After confirmation of eligibility, volunteers were admitted to the clinical research unit 1 day (day 0) prior to randomization. On day 1, volunteers were assigned to a cohort and randomized 3 : 1 (PF-06741086/placebo) to receive a single dose of study drug. Volunteers in the Japanese cohort were assigned to a dose level previously demonstrated to be safe and well tolerated, and thus all received PF-06741086.
Following dosing, volunteers remained as inpatients in the clinical research unit for 7 days for safety, pharmacokinetic (PK), PD and immunogenicity monitoring. All volunteers in each cohort were required to return for weekly outpatient follow-up visits (e.g. day 14 and day 21) to at least day 42 postdose. Volunteers assigned to low-dose cohorts completed the study at day 42 postdose, whereas volunteers assigned to high-dose cohorts completed the study at day 84 postdose. The determination of low-dose versus high-dose status for each cohort was made by the sponsor after evaluation of all available PK (maximum concentration [C max ], area under the curve [AUC], etc.) and PD data and projections for time until PK exposure would be below detectable levels.
Data collected from volunteers during the periods of admission and subsequent follow-up were reviewed to determine whether PF-06741086 was safe and well tolerated. Dosing of volunteers in any cohort may have been stopped if the B7841001 protocol-specified stopping criteria were met (Table S1 ). If available safety and PK data through study day 7 (at a minimum) were permissive for dose escalation, additional volunteers were to be recruited into the next dose escalation cohort in the study and dosed at a level of PF-06741086 conferring greater PK exposure. Completion of dose escalation in B7841001 occurred following the last visit of the final dosed cohort of non-Japanese volunteers.
Dose rationale
Nominal doses planned for cohorts following the 30-mg subcutaneous starting dose were 100 mg and 300 mg for subcutaneous administration, and 150, 300, 1000 and 2000 mg for intravenous administration (Fig. S1 ). The dose level for the Japanese cohort was planned to be less than or equal to the current maximum tolerated dose, via the same route of administration, which had previously been demonstrated to be safe and well tolerated versus a placebo control, at the time of cohort enrollment. The planned doses were selected to provide coverage for the projected efficacious dose of PF-06741086.
Investigational product
PF-06741086 solution for injection, 100 mg mL À1 , was administered via the subcutaneous route or the intravenous route. To limit variability in the assessment of injection tolerability, body locations of the subcutaneous injection(s) were limited to the front of the middle thigh, including anterolateral, or outer area of the upper arm. Multiple injections wrere made at different sites where possible, to limit the injection site volume to 1 mL. Intravenous doses were administered via a syringe pump through an intravenous infusion set.
Endpoints and statistical analysis
The primary endpoints for this study were assessments of the safety and tolerability of PF-06741086 following administration of single doses via the subcutaneous and intravenous routes (Table S2 ). The secondary endpoints included measures for pharmacokinetics, pharmacodynamics, and immunogenicity. No formal sample size calculation was performed for this study. The total planned sample size of~56 volunteers for eight cohorts was based on clinical considerations to balance the need to minimize exposure of study volunteers to the test substance with the need to provide adequate safety, tolerability and PK and PD information at each dose level. Data were summarized descriptively for each cohort and the overall study. Safety monitoring endpoints included laboratory parameters that may be modulated because of inflammation or immune response (C-reactive protein), coagulopathy , and parameters to screen for possible thrombotic events (cardiac troponin I). Laboratory endpoints to detect excessive modulation of the coagulation pathway (PT/INR, APTT, fibrinogen, platelets, AT, and, where applicable, D-dimer) were monitored during the period of peak drug exposure until day 28 postdose. PK samples, beginning at predose and 1 h postdose, were collected throughout the study (day 1 to day 42 or day 84), and analyzed with a validated, sensitive and specific electrochemiluminescence (ECL) method in compliance with Pfizer's standard operating procedures (SOPs) by Quest Pharmaceutical Services (QPS, Newark, DE, USA).
Target binding by PF-06741086 was assessed by measuring total TFPI levels, which were analyzed with a validated, sensitive and specific HPLC tandem mass spectrometry method in compliance with Pfizer's SOPs at PPD (Richmond, VA, USA). 
Results
Volunteer disposition and demographics
A total of 41 volunteers were enrolled in this study: 32 were dosed with PF-06741086 and nine were dosed with placebo across five dose levels (six cohorts; Fig. 1 ). One volunteer left the study prematurely (adverse event [AE]), and an additional volunteer was recruited and dosed to fulfill the enrollment requirement for the affected cohort. All 41 volunteers were included in the analysis of safety, and PK, PD and immunogenicity data.
Cohorts 1-4 were designated as low-dose cohorts, and cohort 5 was designated as a high-dose cohort. The dose for cohort 5 was modified from the prespecified nominal dose of 300 mg intravenously to 440 mg intravenously following completion of the 150-mg intravenous dose cohort. This change was made to provide additional exposure margin coverage versus the projected steadystate C max of the maximum subcutaneous dose level for future repeat dose studies. In addition, it was determined by the sponsor that the exposures (C max and AUC 168 ) achieved following completion of dosing at the 440-mg intravenous dose level provided sufficient coverage to proceed to a subsequent multiple-dose study of PF-06741086 in hemophilic patients, and thus the decision was made to terminate dose escalation. Therefore, on the basis of the absence of any justification for exposing healthy volunteers to higher dose levels, cohorts 6 and 7 were not enrolled in this study.
The demographic characteristics of the study volunteers were balanced between cohorts and between PF-06741086-treated and placebo-treated volunteers. All 41 volunteers were male, and the majority were of White ethnicity (33 of 41 volunteers). Volunteers ranged in age from 19 years to 55 years, with a mean (standard deviation [SD]) of 36.1 years (10.6 years), and had a mean (SD) BMI of 23.9 kg m À2 (3.1 kg m
À2
).
Safety
There were no serious AEs (SAEs) or severe AEs reported following single doses of PF-06741086, and there were no injection or infusion site reactions. One volunteer (30 mg of PF-06741086 subcutaneously; cohort 1) left the study because of an AE (toothache, day 3 postdose) that was determined to be unrelated to PF-06741086. A total of 35 AEs occurred in all volunteers treated with PF-06741086, and 16 of these were considered to be related to treatment. There was no apparent exposure (C max )-related difference in the frequency of AEs, with or without respect to treatment relatedness ( Table 1) . The most common treatment-related AEs were headache, fatigue, and local or generalized pain/discomfort. Treatment-emergent hematology and serum chemistry laboratory abnormalities were seen across PF-06741086 dose levels. The most common changes were increases in hsCRP (six volunteers with hsCRP > 1.0 9 upper limit of normal [ULN]), increases in monocyte counts (six volunteers with counts > 1.2 ULN), and decreases in platelet counts (four volunteers with counts < 0.77 9 baseline count, all within the normal range). No changes in hematology or serum chemistry labratory findings met the prespecified stopping criteria for dose escalation.
There were no treatment-emergent changes in electrocardiography parameters that met the prespecified quantitative criteria for clinical significance or stopping criteria for dose escalation. Two instances of vital sign changes met the prespecified quantitative criteria. At the 150-mg intravenous dose level (cohort 4), two volunteers experienced an increase in diastolic blood pressure of ≥ 20 mmHg from baseline at day 14 and day 28 postdose, respectively. These transient changes in blood pressure were not temporally associated with PF-06741086 administration, and were deemed to be not clinically significant and probably attributable to extraneous causes, and thus did not meet the stopping criteria for dose escalation. No similar findings were seen at the 440-mg intravenous dose level (cohort 5). There were no treatment-emergent abnormalities in the results of assays screening for coagulopathy or possible thrombotic events (PT, APTT, fibrinogen, AT, platelets, and cardiac troponin I), or any changes in these values that met the prespecified stopping criteria. The maximum changes from baseline in these parameters were analyzed to assess the extremes of possible PF-06741086 pharmacology-related effects. The longest prolongation in PT from baseline was a median of 1.0 s (30 mg subcutaneously, cohort 1). The longest prolongation in APTT from baseline was a median of 3.8 s (150 mg intravenously, cohort 4). The largest decrease in fibrinogen levels from baseline was a median of 45 mg dL À1 (440 mg intravenously, cohort 5). The largest decrease in AT activity levels from baseline was a median of 8.5% (440 mg intravenously, cohort 5). There were no detectable levels of cardiac troponin I elevation in any volunteers. There were no clear exposure-related trends in the maximum changes from baseline in any coagulopathy or thrombosis screening laboratory findings, although the greatest changes in fibrinogen and AT were seen at the highest dose studied (Fig. 2) .
Pharmacokinetics
The pharmacokinetics of PF-06741086 were characterized following subcutaneous and intravenous dosing (Fig. 3A) . Following subcutaneous administration, C max was generally reached, with median time to C max (T max ) ranging from 48 h to 72 h, and individual volunteer T max values ranging from 48 h to 144 h ( Table 2) . After the achievement of C max , concentrations declined slowly, with a trend towards a longer apparent half-life (t 1/2 ) at higher doses. The mean t 1/2 ranged from 33.3 h for the 100-mg subcutaneous dose to 65.8 h for the 300-mg subcutaneous dose. Following intravenous administration, C max was observed at or shortly after the end of the 1-h infusion, and concentrations declined in a monophasic fashion. The mean terminal t 1/2 for intravenous administration was 43.6 h for the 150-mg intravenous dose and 79.5 h for the 440-mg intravenous dose. Following intravenous administration, the mean clearance was low, at 0.0575 L h À1 and 0.0306 L h À1 for the 150-mg and 440-mg intravenous doses, respectively, and the mean volume at steady state values were 3.5 L and 3.9 L. With both the subcutaneous and intravenous routes, exposures (particularly the AUC) appeared to increase greater than proportionally with dose on the basis of dosenormalized area under concentration-time curve from time 0 to infinity (AUC inf ) and C max , which suggests that PF-06741086 undergoes target-mediated drug disposition (TMDD). Variability in PF-06741086 exposure based on geometric percentage coefficient of variation for AUC inf and C max was higher for subcutaneous administration (25-287%) than for intravenous administration (5-19%).
Pharmacodynamics
Increasing total plasma TFPI levels (a summary measure of TFPI bound and unbound to PF-06741086) were observed, indicative of target binding (Fig. 3B) . Consistent with the inhibition of TFPI, pharmacological effects reflective of coagulation pathway activation, which include parameters generated in vivo (F 1 + 2 and D-dimer), as well as parameters measured ex vivo (dPT and TGA parameters [lag time, peak thrombin generation, and endogenous thrombin generation potential]), were demonstrated following PF-06741086 administration (Fig. 4) . The responses were generally exposure-dependent. Pharmacological effects on total TFPI levels, as well as on F 1 + 2 , TGA lag time, TGA peak thrombin generation, and D-dimer, persisted for > 168 h following administration of a single dose of 300 mg subcutaneously. Relative to published data, modulation of peak thrombin was not excessive [9] . Similar responses were observed for the single cohort of Japanese volunteers. Whereas changes were observed at all dose levels for some PD endpoints, others were observed at a higher dose level (e.g. D-dimer, F 1 + 2 and dPT at ≥ 100 mg, and total TFPI at ≥ 150 mg). Maximum or near-maximum effects occurred most frequently following a single dose of 300 mg subcutaneously, based on values of maximum change from baseline and on the AUC.
Immunogenicity
The presence of ADA and NAb was evaluated up to day 42 and day 84 for the low-dose and high-dose cohorts, respectively. The presence of ADA (defined as any sample with titers above the assay cut-point) was detected in 15 of 32 volunteers (47%) dosed with PF-06741086. The reported titer (log10) ranged from 1.98 to 3.21, with a negative titer reported as < 1.88. One volunteer had a predose ADA-positive sample. The earliest postdose ADA positive result occurred at day 14, and the latest result occurred at day 42. There were no ADA-positive samples from placebo-treated volunteers or from any volunteer dosed with 30 mg of PF-06741086 subcutaneously.
Of the 15 volunteers who tested positive for ADA, three tested positive for NAb, with each having one positive NAb result on day 42 only. The reported titers (log10) ranged from 1.44 to 1.55, with a negative result reported as < 1.08. All three volunteers with NAb-positive samples were dosed with 300 mg of PF-06741086 subcutaneously. One of the three volunteers who were positive for NAb was dosed in the Japanese cohort. 
Discussion
An alternative approach to therapy for patients with hemophilia A or B is to bypass the need for FVIII or FIX replacement by augmenting the extrinsic coagulation pathway [10] [11] [12] [13] [14] . TFPI is a potent negative regulator of the extrinsic pathway, so inhibition of TFPI may promote coagulation in patients with hemophilia A or B by increasing extrinsic pathway activity [15] . In addition to bypassing the need for replacement factors and the adverse impact of antifactor inhibitors on efficacy, an antibody targeting TFPI has the added potential advantages of a long circulating half-life, subcutaneous administration, and low immunogenicity with no endogenous homolog that can be affected by antibody immune responses.
B7841001 was a first-in-human clinical study designed to evaluate single doses of a novel mAb targeting TFPI, i.e. PF-06741086, which targets the K2 domain of TFPI to prevent the negative regulation of FX activation via the extrinsic coagulation pathway. Single subcutaneous doses of 30, 100 and 300 mg, along with intravenous doses of 150 mg and 440 mg, were administered safely to a healthy volunteer population (n = 32) with normal coagulation factor levels, and were generally well tolerated.
AEs following PF-06741086 administration in this population were consistent with the AE profiles for placebo in phase 1 healthy volunteer studies. There were no SAEs, no severe AEs, and no injection or infusion site reactions, the majority of AEs were mild in severity, and there were no dose-limiting toxicities. Results regarding laboratory parameters, including PT, APTT, fibrinogen, AT, and platelets, showed no evidence of excessive procoagulant activity. These results, obtained in healthy volunteers with normal levels of FVIII and FIX, support the rationale that concomitant treatment of hemophilia A or B patients, respectively, with FVIII or FIX products, against a background of treatment with PF-06741086, is not associated with excessive thrombotic risk. The risk of thrombosis for patients with inhibitors, treated with bypass agents concurrently with PF-06741086, may only be established in clinical trials of PF-06741086. However, in vitro combination spike-in experiments of PF-06741086 and recombinant FVIIa in hemophilic patient plasma did not indicate excessive thrombin generation [16] .
PK profiles indicate that PF-06741086 undergoes TMDD at low doses. The PK profile of the 300 mg subcutaneuous dose level indicates that this single dose is sufficient to maintain a concentration of > 5000 ng mL À1 for > 168 h (i.e. 7 days). The AUC 168 values also exceeded the predefined targeted concentration of 2247 ng mL À1 (i.e. the EC 90 of the dPT assay derived from a study in normal cynomolgus monkeys), which will maximize the chance of achieving efficacy in in trials with repeat dosing in hemophilic patients [14] . The rise in total plasma TFPI levels, a measure of both free and antibody-complexed TFPI, observed at PF-06741086 doses of 300 mg subcutaneously and 150 mg and 450 mg intravenously reflects exposure levels exceeding the TMDD threshold, resulting in a reduction in plasma TFPI turnover. It is likely that TFPI in complex with PF-06741086 has a prolonged half-life relative to free TFPI, and the increase reflects accumulation of the complex. Consistent with this, we observed continued procoagulant PD effects despite increases in total TFPI. Unlike the anti-TFPI aptamer BAX 499, PF-06741086 targets the K2 domain of TFPI, the domain that inhibits FXa activity [17] . Therefore PF-06741086-mediated increases in total plasma levels of TFPI should correlate with procoagulant effects, and should not result in increased FXa inhibition or in the increased bleeding tendency that was observed when hemophilic patients were treated with BAX 499 [18] .
A procoagulant pharmacological effect of PF-06741086 was demonstrated on the basis of multiple coagulation parameters, with a near-maximum effect occurring most frequently with 300 mg subcutaneously, with a duration of effect at that dose level for at least 168 h. The magnitude and duration of the pharmacological effects of PF-06741086 are generally similar to those following single doses (in healthy volunteers and hemophilic patients) of another mAb, concizumab, which also targets the K2 domain of TFPI [11] . In the absence of any dose-limiting toxicities, these results provide a rationale for testing a once-weekly subcutaneous treatment regimen of PF-06741086 in individuals with severe hemophilia A or B.
In this study, the frequency of NAb-positive samples was substantially lower than that of ADA-positive samples. Interference by circulating TFPI may have contributed to the high frequency of positive results reported in the ADA assay. The NAb assay was developed subsequent to the ADA sample analysis in this study. Inclusion of a TFPI target-blocking step, with an epitope-blocking antibody, may have addressed the target interference challenge faced by the ADA assay. Three subjects from the PF-06741086 300-mg subcutaneous cohort each had one positive NAb result on day 42 only. These NAb samples were low-titer, and no subsequent samples were collected from these subjects. Therefore, it is not possible to determine whether the NAbs were persistent or transient. The presence of either ADA or NAb did not appear to have any effect on pharmacokinetics or pharmacodynamics, or the impact could not be evaluated, as the drug concentration was near/below the detection limit, and PD effects had mostly returned to baseline at the time when those ADAs or NAbs were detected.
Some restrictions in the interpretation of study results include the limited safety, tolerability and immunogenicity data, which were obtained from a single-dose study in a healthy volunteer population that excluded individuals with increased thrombotic risk. Because of the small sample sizes recruited, variability is seen in some PD assays (e.g. dPT, which measures activity of the extrinsic pathway). In this study, target engagement was assessed according to total TFPI levels (both bound and unbound to PF-06741086). The effect of PF-0674186 on free TFPI levels (TFPI unbound to PF-0674186) could not be measured, owing to technical challenges related to assay interference by the drug. Also, characterization of the antibody immune response to PF-06741086 was limited in this study. Additional studies are required to further characterize the incidence, magnitude, duration and effect on the pharmacokinetics and pharmacodynamics of ADA and NAb immune responses.
In summary, single doses of PF-06741086, from 30 mg subcutaneously to 440 mg intravenously, were shown to be safe and well tolerated. In addition, PK and PD data © 2018 International Society on Thrombosis and Haemostasis provide sufficient justification to proceed to a phase 1b multiple-dose study (B7841002, NCT02974855, currently ongoing) in patients with hemophilia. Data from this ongoing study are intended to reveal the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and prophylaxis efficacy of PF-0671086 in the severe hemorrhagic condition of hemophilia A or B.
Addendum M. Cardinal, S. Arkin, and P. Sun participated in the study design. C. Kantaridis was a study investigator. C. Kantaridis enrolled patients, and participated in the collection and assembly of data. M. Cardinal, C. Kantaridis, T. Zhu, P. Sun, D. D. Pittman, J. E. Murphy, and S. Arkin participated in data analysis, data interpretation, and manuscript preparation, review, and revisions. All authors granted final approval of the manuscript for submission. L. Schoch, D. Jani, J. Zhang, R. Giovanelli, J. Wisniewski, F. Hua, and W. Denney, for their work in executing this study. This study was sponsored by Pfizer Inc. Editorial support was provided by T. O'Neill of Peloton Advantage and was funded by Pfizer Inc.
Disclosure of Conflict of Interests
All authors are employees of Pfizer Inc. and own stock/ options in the company.
Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article: Table S1 . Dose escalation and stopping criteria. Table S2 . Primary and secondary endpoints. Fig. S1 . Planned dose escalation scheme.
